Frequency of BCR-ABL Transcript Types in Syrian CML Patients

Table 2

Frequency of BCR-ABL transcript types among CML patient groups ().

Patient group	BCR-ABL transcript types
	b2a2	b3a2	b3a3	e1a3
Imatinib-treated patients ()
BCR-ABL ≤ 0.1% ()	6 of 10 (60%)	1 of 10 (10%)	1 of 10 (10%)	2 of 10 (20%)
BCR-ABL > 0.1% ()	3 of 8 (37.5%)	4 of 8 (50%)	1 of 8 (12.5%)	0 of 8 (0%)
Noncompliant patients ()	5 of 6	0 of 6	1 of 6	0 of 6

Dual transcripts were detected in three patients, which explains reporting 24 transcripts in 21 patients.
Independence of BCR-ABL transcript types among imatinib-treated patients according to their molecular response was analyzed by Fisher’s exact test. value < 0.05 was considered significant.